MARKETS SPECTATOR: Newcrest's lost lustre

Newcrest's big write-down has sent analysts back to their spreadsheets.

Newcrest’s $6 billion write off surprised an analyst or two.

“We had previously contemplated a write-down but not incorporated it into our base case having determined it was low probability given the long asset life,” writes Morgan Stanley analyst Brendan Fitzpatrick. “Now we do. It is a non-cash event but will increase gearing to 26 per cent on our forecasts”.

The fall in the gold price and potential write offs has led Fitzpatrick to cut his earnings per share forecast for Newcrest, Australia’s biggest publicly traded gold miner.

The spot price for gold today fell $3.08, or 0.2 per cent, to $US1,383.42 a troy ounce, according to Bloomberg data. The spot price of gold, in US dollars, has fallen 17 per cent this year, according to Bloomberg.

In the 12 months to June 30, 2013, Fitzpatrick forecasts Newcrest’s earnings per share to be 66 cents compared with an earlier forecast of 72 cents. He expects the company’s earnings per share in 2014 to be 70 cents compared with an earlier forecast of $1.01.

The Morgan Stanley analyst expects Newcrest to pay no dividend in 2013 and 2014.

“A lower gold price would continue to add to operational pressure,” says Fitzpatrick. His target price for the stock is now $13 compared with a previous $16 forecast.

At 1416 AEST Newcrest shares were down 33 cents, or 2.7 per cent, to $12.02. The stock has plunged 21 per cent since May 5.

The S&P/ASX200 Index was up 14.197, or 0.3 per cent, to 4,751.90. The index has lost 3 per cent since May 5.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles